Meridian bioscience stock.

Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 33.33% and 2.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Meridian bioscience stock. Things To Know About Meridian bioscience stock.

About Meridian Bioscience, Inc. Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products.Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced that it has entered into a side letter with the buyer ...TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks.comMeridian to be acquired by SD Biosensor, SJL Partners for $1.53B. A high-level overview of Meridian Bioscience, Inc. (VIVO) stock. Stay up to date on the latest …Dec 19, 2022 · The estimated Net Worth of Bryan T Baldasare is at least $2.96 Million dollars as of 8 February 2021. Mr. Baldasare owns over 6,254 units of Meridian Bioscience stock worth over $1,906,668 and over the last 4 years he sold VIVO stock worth over $566,813. In addition, he makes $490,759 as Chief Financial Officer, Senior Vice …

About Meridian Bioscience, Inc. Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products.Meridian Bioscience, Inc. is a life science company. The Company is engaged in the development, manufacture, sale and distribution of diagnostic testing systems and kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels; and the manufacture and distribution of bulk antigens, antibodies, immunoassay blocking reagents, specialized ...

7 juil. 2022 ... Meridian Biosciences (VIVO) Stock Trending on $1.5 Billion Buyout Agreement · Meridian Bioscience (VIVO) agreed to be acquired by SD Biosensor ...

Looking at the universe of stocks we cover at Dividend Channel, on 5/1/13, Meridian Bioscience Inc. (NASD: VIVO) will trade ex-dividend, for its quarterly dividend of $0.19, …Meridian Bioscience (NASDAQ:VIVO) is a fully-integrated developer of diagnostic systems through its diagnostics segment, ... That means Meridian is a highly valued stock right now, ...The estimated Net Worth of James M. Anderson is at least $1.07 Million dollars as of 6 January 2023. Mr. Anderson owns over 8,500 units of Meridian Bioscience stock worth over $958,769 and over the last 14 years he sold VIVO stock worth over $0. In addition, he makes $114,667 as Independent Director at Meridian Bioscience.Under the terms of the agreement, Meridian shareholders will receive $34.00 per share in cash, which represents a premium of approximately 32% over Meridian's closing stock price on the day before ...Dec 19, 2022 · The estimated Net Worth of Bryan T Baldasare is at least $2.96 Million dollars as of 8 February 2021. Mr. Baldasare owns over 6,254 units of Meridian Bioscience stock worth over $1,906,668 and over the last 4 years he sold VIVO stock worth over $566,813. In addition, he makes $490,759 as Chief Financial Officer, Senior Vice …

Meridian's website address is www.meridianbioscience.com. Contact: Charlie Wood Vice President – Investor Relations Meridian Bioscience, Inc. Phone: +1 513.271.3700 Email: [email protected]

Other Medical Equipment, Supplies & Distribution. Meridian Bioscience, Inc. (0K0K.LON) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock …

Jan 31, 2023 · John has made over 6 trades of the Meridian Bioscience stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of VIVO stock worth $37,950 on 25 February 2020.Summary of all time highs, changes and price drops for Meridian Bioscience; Historical stock prices; Current Share Price: US$33.97: 52 Week High: US$34.38: 52 …South Korean billionaire Cho Young-sik’s SD Biosensor and Seoul-based private equity firm SJL Partners said they are acquiring Nasdaq-listed diagnostics company Meridian Bioscience for $1.53 ...Meridian Bioscience Careers. Carrière. Benefits. Les avantages sociaux. Open Positions. Consulter les offres d'emploi. Life Science. Back; Products ... If the starting stock is a 25 mM solution of each dNTP in a 100mM dNTP Mix, you need to add 0.5 µL to a 50 µL standard PCR reaction.Under the terms of the agreement, Meridian shareholders will receive $34.00 per share in cash, which represents a premium of approximately 32% over Meridian's closing stock price on the day before ...

Meridian Bioscience, Inc. is a life science company. The Company is engaged in the development, manufacture, sale and distribution of diagnostic testing systems and kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels; and the manufacture and distribution of bulk antigens, antibodies, immunoassay blocking reagents, specialized ...Feb 1, 2023 · Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms ... Jan 31, 2023 · The estimated Net Worth of John P. Kenny is at least $17.5 Million dollars as of 24 June 2022. Mr Kenny owns over 74,996 units of Meridian Bioscience stock worth over $11,093,515 and over the last 6 years he sold VIVO stock worth over $4,939,280. In addition, he makes $1,508,705 as Pres and CEO & Director at Meridian Bioscience.Summary. Meridian Biosciences released an update saying it set the closing date for its merger on Jan. 31. The stated reason is that the acquiring parties wanted some extra time to get the financing.8 Jul 2022 ... That represents a 32% premium to Meridian's closing stock price of ... “We are pleased to be a family with Meridian Bioscience as a great ...About After Hours Quotes. Nasdaq provides market information on after hours trading daily from 4:15 p.m. ET to 3:30 p.m. ET on the following day. Meridian Bioscience Inc. Common Stock (VIVO) After ...100% technical buy signals. 8 new highs and up 15.79% in the last month. 4,910 investors are monitoring the stock on Seeking Alpha. ... Meridian Bioscience, Inc., a life science company ...

VIVO stock is in the headlines as the company discloses a financial update. Meridian Bioscience ( VIVO) agreed to be acquired by SD Biosensor and SJL Partners in a $1.53 billion deal. Also, the ...

Meridian stock will no longer be traded on the NASDAQ Global Select Market. Meridian will continue to operate as an independent entity, under new …Meridian is an Ohio corporation and, therefore, governed by the corporate laws of Ohio. Since its stock is publicly traded on Nasdaq and it files reports with the Securities and Exchange Commission, it is also subject to NASD rules as well as various provisions of federal securities laws as recently changed by the Sarbanes-Oxley Act.Oct 11, 2022 · Meridian Bioscience, Inc. is a life science company. The Company is engaged in the development, manufacture, sale and distribution of diagnostic testing systems and kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels; and the manufacture and distribution of bulk antigens, antibodies, immunoassay blocking reagents, specialized ... Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $0.Jan 31, 2023 · The estimated Net Worth of Anthony P Iii Bihl is at least $2.24 Million dollars as of 17 May 2022. Mr. Bihl owns over 20,000 units of Meridian Bioscience stock worth over $2,242,020 and over the last 7 years he sold VIVO stock worth over $0. In addition, he makes $0 as Independent Director at Meridian Bioscience.Jan 31, 2023 · About Meridian Bioscience, Inc. Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products. - 상기 내용은 당사 종속회사인 Columbus Holding Company(CHC)의 100% 출자회사인 Meridian Bioscience, Inc.에 대한 출자 관련 사항임. - 1.발행회사 자본금 ($155,405,000)은 최근 사업연도 말 기준으로, 2023년 11월 22일 서울외국환중개 매매기준율 ...

Marco Calzavara VIVO stock SEC Form 4 insiders trading. Marco has made over 1 trades of the Meridian Bioscience stock since 2013, according to the Form 4 filled with the SEC. Most recently Marco sold 3,200 units of VIVO stock worth $69,792 on 30 May 2013.. The largest trade Marco's ever made was selling 3,200 units of Meridian …

Dec 1, 2023 · Meridian Bioscience, Inc. (NASDAQ:VIVO) issued its earnings results on Friday, November, 12th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $0.03. The company had revenue of $76.20 million for the quarter, compared to analysts' expectations of $68.40 million.

Complete Vivo Collaboration Solutions Ltd. stock information by Barron's. View real-time VIVO stock price and news, along with industry-best analysis.Financial performance achieved by Meridian Bioscience has been rather interesting. After seeing revenue remain almost flat, bouncing around within a range of between $200.8 million and $213.6 ...Diagnostics Solutions. Meridian Bioscience provides best-in-class diagnostic platforms, tests, education, and support to help you deliver answers. Which disease do you need to test for? Meet Revogene ®. Learn more about the innovative Revogene molecular platform.17 Mei 2016 ... Preparing the PCR primer stock and mixes. Hands-on DNA•36K views · 9:39 · Go ... Bioline: Meridian Bioscience•1.2K views · 12:16 · Go to channel ...Meridian Bioscience (NASDAQ:VIVO) is a fully-integrated developer of diagnostic systems through its diagnostics segment, ... That means Meridian is a highly valued stock right now, and the prices ...Oct 11, 2022 · Meridian Bioscience, Inc. is a life science company. The Company is engaged in the development, manufacture, sale and distribution of diagnostic testing systems and kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels; and the manufacture and distribution of bulk antigens, antibodies, immunoassay blocking reagents, specialized ... Jan 31, 2023 · The estimated Net Worth of James M. Anderson is at least 1.07 百万$ dollars as of 6 January 2023. Mr. Anderson owns over 8,500 units of Meridian Bioscience stock worth over 958,769$ and over the last 14 years he sold VIVO stock worth over 0$. In addition, he makes 114,667$ as Independent Director at Meridian Bioscience.Mar 14, 2022 · Financial performance achieved by Meridian Bioscience has been rather interesting. After seeing revenue remain almost flat, bouncing around within a range of between $200.8 million and $213.6 ... Curian is a rapid diagnostic solution for immunoassay detection of gastrointestinal diseases. It quickly and accurately identifies H. pylori, Campylobacter, and Shiga Toxin E. coli active infections. New tests are continuously being added to improve gastrointestinal outcomes and build a healthier community.

1.1 This Israeli Appendix (the “Appendix”) to the Meridian Bioscience, Inc. 2012 Stock Incentive Plan, as amended from time to time (the “Plan”) is made and entered effective as of July 10, 2020 (the “Appendix Effective Date”). The provisions specified hereunder shall form an integral part of the Plan. 1.2 The provisions set forth in this Appendix apply only …Stock split history for Meridian Bioscience (VIVO) Meridian Bioscience stock (symbol: VIVO) underwent a total of 7 stock splits. The most recent stock split occured on May 14th, 2007. One VIVO share bought prior to March 30th, 1992 would equal to 5.47509375 VIVO shares today. Stock split list. DateMar 14, 2022 · Financial performance achieved by Meridian Bioscience has been rather interesting. After seeing revenue remain almost flat, bouncing around within a range of between $200.8 million and $213.6 ... Instagram:https://instagram. schwab municipal bond etfdoes spacex have stocksiemens ag stockworldcoin where to buy Jan 24, 2019 · Meridian Bioscience Inc. Dividend Stock News and Updates. Feb. 05, 2022 VIVO STOCK PRICE INCREASE: Meridian Bioscience Inc. on 02-05-2022 increased stock price > 10% from $21.38 to $23.98. Read more... Jul. 14, 2021 VIVO STOCK PRICE DECREASE: Meridian Bioscience Inc. on 07-14-2021 decreased stock price > 10% from $22.50 to $17.35. Cannabis stocks were little changed Thursday, and the major indices... News. on 7/12/18. Meridian Bioscience gets the ... best cryptocurrency day tradinghow much is a silver bar worth 2023 Meridian is an Ohio corporation and, therefore, governed by the corporate laws of Ohio. Since its stock is publicly traded on Nasdaq and it files reports with the Securities and Exchange Commission, it is also subject to NASD rules as well as various provisions of federal securities laws as recently changed by the Sarbanes-Oxley Act.Meridian Bioscience, Inc. is a life science company. The Company is engaged in the development, manufacture, sale and distribution of diagnostic testing systems and kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels; and the manufacture and distribution of bulk antigens, antibodies, immunoassay blocking reagents, specialized ... schwab us reit etf Jan 30, 2023 · Meridian Bioscience, Inc. is a life science company. The Company is engaged in the development, manufacture, sale and distribution of diagnostic testing systems and kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels; and the manufacture and distribution of bulk antigens, antibodies, immunoassay blocking reagents, specialized ... Dec 1, 2023 · Meridian Bioscience, Inc. (NASDAQ:VIVO) issued its earnings results on Friday, November, 12th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $0.03. The company had revenue of $76.20 million for the quarter, compared to analysts' expectations of $68.40 million.